Abstract
Background: Previous studies suggested that the single nucleotide polymorphisms of Pro12Ala located within the PPARG gene were significantly associated with the T2DM. Recently, the genetic studies on Pro12Ala were conducted in the different ethnic groups and the results of each study were shown to be inconsistent. Moreover, the systematic review has not been updated since 2000.
Objective: To further validate the risk of Pro12Ala for T2DM disease based on the genetic data.
Methods: The genetic studies on the Pro12Ala in the T2DM were searched in the PubMed and PMC database from January 2000 to October 2017. The meta-analysis was conducted with the CMA software.
Results: The meta-analysis collected 14 studies including 20702 cases and 36227 controls. The combined analysis of all studies found that Pro12Ala was shown to be significantly associated with T2DM and the Ala allele played the increasing risks for the disease. Nevertheless, publication bias was detected in the combined analysis. The subgroup analysis indicated that Pro12Ala was found to be significant in the Caucasian and Chinese population. There was no heterogeneity and publication bias in these two groups.
Conclusion: The meta-analysis confirmed the evidence that the Pro12Ala was the susceptible variant for the decreasing risks for the T2DM.
Keywords: PPARG gene, Pro12Ala polymorphism, T2DM, meta-analysis, diabetes mellitus, type 2.
[1]
Gloyn AL, McCarthy MI. The genetics of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2001; 15(3): 293-308.
[2]
Zimmet P, Alberti KG, Shaw JG. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
[3]
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997; 349(9063): 1436-42.
[4]
Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316(5829): 1341-5.
[5]
Scott RA, Scott LJ, Mägi R, et al. An expanded genome-wide association study of type 2 diabetes in europeans. Diabetes 2017; 66(11): 2888-902.
[6]
Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature 2016; 536(7614): 41-7.
[7]
Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Annals New York Acad Sci 2010; 1212(1): 59-77.
[8]
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49(10): 497-505.
[9]
Gouda HN, Gurdeep SS, Anne-Helen H, Jan Y, Manjinder SS, Julian PTH. The association between the peroxisome proliferator-activated receptor-γ2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and meta-analysis. Am J Epidemiol 2010; 171(6): 645-55.
[10]
Li H, Kilpeläinen TO, Liu C, et al. Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia 2012; 55(4): 981-95.
[11]
Delahanty LM, Pan Q, Jablonski KA, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care 2012; 35(2): 363-6.
[12]
Ma J, Li Y, Zhou F, Xu X, Guo G, Qu Y. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator–activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians. Mol Vis 2012; 18: 2352.
[13]
Dora JM, Machado WE, Rheinheimer J, Crispim D, Maia AL. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case–control study and meta-analysis. Eur J Endocrinol 2010; 163(3): 427-34.
[14]
Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol 2013; 32(4): 188-98.
[15]
Ramya K, Radha V, Ghosh S, Majumder PP, Mohan V. Genetic variations in the FTO gene are associated with type 2 diabetes and obesity in south Indians (CURES-79). Diabetes Technol Ther 2011; 13(1): 33-42.
[16]
Pleskovič A, Letonja MS, Vujkovac AC, Starćević JK, Petrovič D. Polymorphisms of the PPAR-γ (rs1801282) and its coactivator (rs8192673) have a minor effect on markers of carotid atherosclerosis in patients with type 2 diabetes mellitus. PPAR Res 2016; 2016: 4934251.
[17]
Gaulton KJ, Ferreira T, Lee Y, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 2015; 47(12): 1415-25.
[18]
Martínez‐Gómez LE, Cruz M, Martínez-Nava GA, et al. A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico. Annals of Human Genetics 2011; 75(5): 612-20.
[19]
Berezin A, Zulli A, Kerrigan S, Petrovic D, Kruzliak P. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. Clin Biochem 2015; 48(9): 562-8.
[20]
Zhu L, Huang Q, Xie Z, et al. PPARGC1A rs3736265 G> A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level. Oncotarget 2017; 8(23): 37308.
[21]
Wang X, Liu J, Ouyang Y, Fang M, Gao H, Liu L. The association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese population. PLoS One 2013; 8(8): e71985.
[22]
Pei Q, Huang Q, Yang GP, et al. PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients’ response to pioglitazone in China. Acta Pharmacol Sin 2013; 34(2): 255-61.
[23]
Cui B, Zhu X, Me Xu , et al. A genome-wide association study confirms previously reported loci for type 2 diabetes in Han Chinese. PLoS One 2011; 6(7): e22353.
[24]
Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep 2014; 16(5): 476.
[25]
Al-Safar H, Hassoun A, Almazrouei S, Kamal W, Afandi B, Rais N. Association of the genetic polymorphisms in transcription factor 7-like 2 and peroxisome proliferator-activated receptors-γ2 with type 2 diabetes mellitus and its interaction with obesity status in Emirati Population. J Diabetes Res 2015; 2015: 1-8.
[26]
Majid M, Masood A, Kadla SA, Hameed I, Ganai BA. Association
of Pro12Ala polymorphism of peroxisome proliferator-activated
receptor gamma 2 (pparγ2) gene with type 2 diabetes mellitus in
ethnic kashmiri population. Biochem gen 2017; 55(1): 10-21.
[27]
Motavallian A, Andalib S, Vaseghi G, Mirmohammad-Sadeghi H, Amini M. Association between PRO12ALA polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in Iranian patients. Indian J Hum Genet 2013; 19(2): 239.
[28]
Pattanayak AK, Bankura B, Balmiki N, Das TK, Chowdhury S, Das M. Role of peroxisome proliferator‐activated receptor gamma gene polymorphisms in type 2 diabetes mellitus patients of West Bengal, India. J Diabetes Investig 2014; 5(2): 188-91.
[29]
Chauhan G, Spurgeon CJ, Tabassum R, et al. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes 2010; 59(8): 2068-74.
[30]
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88.
[31]
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 1088: 1101.
[32]
Egger M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[33]
Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19(4): 251-3.
[34]
Villegas R, Xiang YB, Elasy T, et al. Fish, shellfish, and long-chain n− 3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. Am J Clin Nutr 2011; 94(2): 543-51.
[35]
Priya SS, Sankaran R, Ramalingam S, Sairam T, Somasundaram LS. Genotype phenotype correlation of genetic polymorphism of PPAR gamma gene and therapeutic response to pioglitazone in type 2 diabetes mellitus-a pilot study. JCDR 2016; 10(2): FC11.
Article Metrics
50
7
1
1